Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|9|2|115-123

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.9, Iss.2, 2014-06, pp. : 115-123

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 1, 2018-01 ,pp. : 19-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

JTK-853, a Novel Non-Nucleoside Hepatitis C Virus Polymerase Inhibitor, Demonstrates a High Genetic Barrier to Resistance in vitro

By  

Intervirology, Vol. 56, Iss. 5, 2013-07 ,pp. : 302-309

Karger

Access to resources Recommend Favorite

Variations in the Viral NS5B Region in Japanese Patients with Chronic Hepatitis C Virus Genotype 1b Infection

By  

Intervirology, Vol. 49, Iss. 6, 2006-10 ,pp. : 319-326

Karger

Access to resources Recommend Favorite

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 710-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ‐56914845 (GSK2336805) in subjects with hepatic impairment

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 9, 2015-09 ,pp. : 1042-1050

John Wiley & Sons Inc

Access to resources Recommend Favorite